EarningsQ3 2024 Earnings Report

Sumitomo Dainippon Pharma Co (DPM) Q3 2024 Earnings Report

0 Followers

Previous Report: Q2 2024

Next Report: Q4 2024

DE:DPM Q3 2024 EPS Results

Actual EPS€0.76

Consensus EPS€0.23

Beat/MissBeat by +€0.53

One Year Ago EPS-€0.71

DE:DPM Q3 2024 Revenue Results

Actual Revenue€633.97M

Expected Revenue€522.45M

Beat/MissBeat by +€111.52M

YoY Revenue Growth+36.47%

Earnings Announcement Details

QuarterQ3 2024

Date01/31/2025

TimeTBA

Conference CallFriday, January 31, 2025

DE:DPM Upcoming Earnings

Sumitomo Dainippon Pharma Co's next earnings date is estimated for October 30, 2026, based on past reporting schedules.

Q3 2024 Earnings Call Audio

DE:DPM Q3 2024 Earnings Call

0:00 / 0:00

Q3 2024 Earnings Slide Deck

Q3 2024 Earnings Call Summary

Q3 2024

Earnings Call Date:Jan 31, 2025|

% Change Since:

Earnings Call Sentiment|Negative

The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.

Company Guidance

During the Q3 2024 earnings call for Sumitomo Pharma, several key financial metrics and strategic adjustments were discussed. Revenue for Q3 2023 was reported at JPY 235 billion, which marked a significant decrease of JPY 225.2 billion from the same period in the previous year. The decline was attributed to reduced revenue across all segments, including Japan, North America, and Asia. Despite a decrease in SG&A expenses and some operating income from the sale of shares in Sumitomo Pharma Animal Health, the core operating profit decreased by JPY 139.3 billion, resulting in a core operating loss of JPY 96.4 billion. The company also recorded a JPY 20.5 billion nonrecurring expense related to restructuring in North America, contributing to an operating loss of JPY 117.7 billion. Additionally, profit before taxes saw a year-on-year decrease of JPY 107.4 billion, resulting in a quarterly loss of JPY 105.2 billion. Consequently, the net profit attributable to owners of the parent decreased significantly, resulting in a loss of JPY 117.7 billion. The full-year financial forecast was revised downward, with expectations for revenue at JPY 317 billion, a reduction of JPY 45 billion from previous forecasts. The forecasted core operating profit was expected to see a reduction of JPY 72 billion, projecting a loss of JPY 134 billion. The company is also anticipating a decrease in profit attributable to owners by JPY 61 billion, forecasting a loss of JPY 141 billion. The underperformance was largely due to the North American segment, where key products like ORGOVYX, MYFEMBREE, and GEMTESA fell short of their sales plans.

Development Progress in iPS Cell-Derived Therapies

Significant progress in clinical development in regenerative medicine, particularly in Parkinson's disease using iPS cell-derived dopaminergic progenitor cells. The University of California San Diego began a study in November 2023, with ongoing trials in Japan.

Oncology Pipeline Advancements

Promising interim results for TP-3654 in myelofibrosis and DSP-5336 in acute leukemia, with observed reductions in spleen volume and bone marrow blasts respectively, and good tolerability in trials.

DE:DPM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Oct 30, 2026	2026 (Q2)	0.16 / -	1.244	―
Jul 31, 2026	2026 (Q1)	0.11 / 0.22	0.159	38.32% (+0.06)
May 13, 2026	2025 (Q4)	-0.09 / -0.01	0.034	-133.55% (-0.05)
Jan 30, 2026	2025 (Q3)	>-0.01 / 0.13	0.759	-83.51% (-0.63)
Oct 31, 2025	2025 (Q2)	0.45 / 1.24	-0.684	281.99% (+1.93)
Jul 31, 2025	2025 (Q1)	0.11 / 0.16	0.226	-29.67% (-0.07)
May 13, 2025	2024 (Q4)	-0.07 / 0.03	-3.509	100.98% (+3.54)
Jan 31, 2025	2024 (Q3)	0.23 / 0.76	-0.709	206.97% (+1.47)
Oct 30, 2024	2024 (Q2)	0.10 / -0.68	-0.41	-66.78% (-0.27)
Jul 31, 2024	2024 (Q1)	-0.06 / 0.23	-0.552	141.00% (+0.78)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed